Commercial vaccine strength Dynavax is a commercial-stage biopharmaceutical company with HEPLISAV-B, a globally approved hepatitis B vaccine, and CpG 1018 adjuvant licensed for multiple vaccines. Upsell opportunities exist by expanding adjuvant use in partner vaccines or leveraging their established market access in the US, EU, and UK.

Sanofi affiliation As a Sanofi company, Dynavax may have access to larger distribution channels, co-development opportunities, and potential strategic partnerships. Explore channel alignment, co-promotional ventures, and cross-sell of CpG 1018 adjuvant within Sanofi’s vaccine portfolio.

Clinical pipeline Dynavax is advancing novel vaccines including a shingles candidate Z-1018 with positive topline Phase 1/2 data. There is a path for BD focus on licensing deals, milestone-based partnerships, or collaboration to accelerate commercialization of late-stage or partnered programs.

Financial scale Revenue range ($100M-$250M) and substantial funding ($1.6B) indicate a growth-ready company with potential for partner-funded commercialization, co-development, or supply agreements for expanded manufacturing capacity to meet rising vaccine demand.

Market positioning Two established products and a broad adjuvant platform position Dynavax as a versatile vaccine partner. Target opportunities include adjuvant-enabled vaccines in infectious disease pipelines, regional expansion initiatives, and collaborations with large biologics players seeking adjuvant optimization.